CBII.CN - CB2 Insights Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.0750
+0.0050 (+7.14%)
At close: 3:47PM EDT
Stock chart is not supported by your current browser
Previous Close0.0700
Open0.0000
Bid0.0650 x 0
Ask0.0750 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume82,390
Market Cap6M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1010
Earnings DateNov. 07, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    CB2 Insights Launches Industry’s First Medical Cannabis Insights Dashboard for All Medical Cannabis Stakeholders

    CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has launched the medical cannabis industry’s first interactive dashboard which gives any industry stakeholders access to key patient insights derived from the Company’s clinical operations. The tool (link: https://cb2insights.ca/data) is free to use and was created in order to answer hundreds of inbound questions from global industry stakeholders including government agencies and major research groups. The dashboard also allows users to submit additional data requests directly to the Company’s research and data team.

  • GlobeNewswire

    CB2 Insights Appoints Healthcare Industry Expert and Former IQVIA Executive Tom Brogan to its Board of Directors

    CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, is pleased to announce the appointment of Tom Brogan, as an independent director to CB2’s Board of Directors. Effective immediately, Mr. Brogan will replace outgoing Directors, David Danziger and Gerry Goldberg, who wish to pursue other opportunities.

  • GlobeNewswire

    CB2 Insights Announces Completion of Payment of New Jersey Alternative Medicine

    CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announces it has completed all payment obligations for the June 2019 acquisition of New Jersey Alternative Medicine (“NJAM”). Based on revised terms, the Company will issue 2.5 million common shares to be escrowed over 15 months with a rolling release over the term. Based on the original Agreement, the Company would have seen a total purchase consideration payout of approximately $800,000.

  • GlobeNewswire

    CB2 Insights Selected by Vireo Health to Support Medical Cannabis Clinical Trial

    CB2 chosen to advance application with the US FDA for study on safety and efficacy of cannabis-based topical treatments by leading multistate operator, Vireo. Project marks the start of the clinical trial process for Vireo’s topical creams, lotions and gels to be used by patients for pain management. Company will develop full protocols and manage Investigational New Drug (IND) application on behalf of Vireo and will work with the FDA towards approvals.

  • GlobeNewswire

    CB2 Insights 2019 Year In Review – A Message from CEO and Co-Founder Pradyum Sekar

    CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today released its CEO’s 2019 Year In Review. The letter, which has also been sent to Investors, provides an update on the growth and development of the business last year as well as the foundation and opportunities that are ahead for 2020. CB2 Insights has been pleased to deliver a year of outstanding performance for 2019, driven by a strong focus on establishing business fundamentals, execution of a well defined business strategy and growth in new business verticals to support a growing global demand for cannabinoid data and research.

  • GlobeNewswire

    CB2 Insights Announces Industry’s First Full-Scale Hemp-based Cannabidiol (CBD) Prospective Trial in Partnership with GL Brands (Formerly Freedom Leaf Inc.)

    CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced that it will begin a prospective trial with GL Brands (FRLF) through its U.S.-based hemp brand and key operating subsidiary, Green Lotus. The study will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules when looking to treat anxiety.

  • GlobeNewswire

    CB2 Insights Completes Full-Scale Platform to Connect Disparate Data Systems

    Company completes full-scale platform development for a cloud-based data aggregation tool specializing in managing disparate data sources into a single platform to structure, clean and apply analytical models to address key health and product-related questions. The cloud-based system will improve efficiencies to clients needing to handle multiple, disparate systems for data collection, clinical trials or other research projects including supporting commercialization and new drug discovery. CB2 will work with existing partners to launch the platform in 2020 and will look to further commercialize across other verticals and customer segments including health networks, regulators and life sciences stakeholders.

  • GlobeNewswire

    CB2 Insights Launches Warrant Incentive Program

    CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence-driven from the point-26of-care to the medical cannabis community, announces a warrant exercise incentive program (the “Program”) which has been implemented to encourage the exercise of the Company’s outstanding warrants. The Warrants are exercisable at a price of $0.09 per Common Share starting December 11, 2019 until December 26, 2019 (the “Early Exercise Period”). The Company has received confirmation that shareholders Merida Capital, Phyto Partners, and other supportive institutional shareholders intend to support the Program.

  • GlobeNewswire

    CB2 Insights Announces Collaboration with FCM Global to Support Medical Cannabis R&D in Colombia

    CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence-driven from the point-of-care to the medical cannabis community, today announced that it is partnering with Licensed Producer FCM Global (“FCM”), the first Colombian cannabis company to be fully licensed in research, cultivation, extraction, distribution and export. The partnership will work to create market access and the design of clinical trials to support the deployment of future FCM cannabinoid-based products. FCM owns and operates a 235,800 sq. ft. production facility in La Ceja, Antioquia, as well as an expanded cultivation and biomass production facility of 474 hectares in Tolima.

  • GlobeNewswire

    CB2 Insights to Participate at Piper Jaffray’s 31st Annual Healthcare Conference

    CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence-driven from the point-of-care to the medical cannabis community, today announced Prad Sekar, CEO of CB2 Insights will be participating in a panel discussion and meeting with investors at Piper Jaffray’s 31st Annual Healthcare Conference on December 3-5, 2019 in New York City. CB2 Insights will join nearly 300 public and private companies in the biotechnology, specialty pharmaceutical, drug discovery and medical technology space. CB2 Insights is one of the leading global voices in the move to mainstream medical cannabis into traditional healthcare.

  • GlobeNewswire

    CB2 Insights Announces Record Revenue of $4.2 million for the Third Quarter 2019; Sequential Growth of 29%

    CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announced its results for the three and nine months ended September 30, 2019. CB2 Insights’ financials are prepared in accordance with International Financial Reporting Standards (“IFRS”). “This was a milestone quarter for us at CB2, it was the first full reporting period that included the contributions of all three clinical businesses.

  • GlobeNewswire

    CB2 Insights Announces Record Preliminary Unaudited Q3 2019 Revenue of $4.2 Million and Details for Earnings Call

    CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announced preliminary unaudited revenue of approximately $4.2 million1  for the three months ended September 30, 2019, representing a 29% growth from the previous quarter. The Company’s achievement in the first nine months of 2019 was, in large part, due to the successful strategic acquisitions of Relaxed Clarity, MedEval Clinics LLC and New Jersey Alternative Medicine (now operating as Canna Care Docs New Jersey). CB2 now successfully owns and operates one of the largest networks of medical cannabis clinics across the US with a patient registry of 100,000 unique visitors annually.

  • GlobeNewswire

    VIVO and CB2 Insights Enter Technology and Research Partnership

    OTCQB: CBIIF) (“CB2”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announced it has entered into a technology and multi-phase research agreement with VIVO Cannabis Inc. (TSX-V: VIVO, OTCQX: VVCIF) (“VIVO”), an Ontario-based cannabis company recognized for its premium products and services, to assist in the development of VIVO’s global medical product development strategy. Under the terms of the agreement, CB2 will be integrating CB2’s Clinical Data Management Software (CDMS) and Electronic Data Capture (EDC) tools to establish better understanding of VIVO’s current medical patient registry.

  • GlobeNewswire

    CB2 Insights Licenses Electronic Data Capture Software to MyAccess Clinics for Use In the UK

    Company strengthens market presence in United Kingdom with licensing of Electronic Data Capture Technology in partnership with UK-based MyAccess ClinicsMyAccess Clinics to use.

  • GlobeNewswire

    CB2 Insights Announces Appointment of Medical Director in Colombia and Enters Market with Cannabis Research Focus

    Company recruits prominent Colombian naturopathic and integrative medicine physician Dr. Paola Cubillos, MD, ND to lead medical cannabis research programs to advance emerging.

  • GlobeNewswire

    CB2 Insights Reports Second Quarter Fiscal 2019 Financial Results, Sees Positive Impact from New Acquisitions

    OTCQB:CBIIF) (“CB2” or the “Company”), a leading technology company focused on mainstreaming medical cannabis to the healthcare industry through Real World Evidence (“RWE”), today reported its results for the second quarter of 2019.  Additional information concerning the Company, including its unaudited financial statements and related management’s discussion and analysis (“MD&A”) for the quarter ended June 30, 2019, can be found at www.sedar.com and on the Company’s website.  All amounts are expressed in Canadian dollars unless otherwise noted.

  • GlobeNewswire

    CB2 Insights Announces New Appointment to Board of Directors with Medical Cannabis and Capital Markets Executive

    OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has appointed corporate finance executive and cannabis industry expert, Gerry Goldberg as Director on its Board.  Mr. Goldberg will immediately assume the position of Chairman of the Audit Committee, replacing David Danziger who will remain in position as Chairman of the Board. The Company also announces that Mr. Goldberg will be replacing outgoing Director Dr. Danial Schecter.

  • GlobeNewswire

    CB2 Insights Adds Former Johnson & Johnson Executive as Director

    OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has appointed former Johnson & Johnson executive Peter Cummins as a Director to its Board, increasing the size of its Board of Directors to seven (7) members. “The high interest and development potential that exists between medical cannabis and traditional healthcare is enormous”, said Mr. Cummins. “CB2 Insights is the bridge between these two industries through clinically-driven observational data which is key to the development of cannabis-based medicine by pharmaceutical companies across the globe.

  • GlobeNewswire

    CB2 Insights Selected by Drug Science as Research Technology Platform for the UK’s Largest Medical Cannabis Pilot

    OTCQB: CBIIT) (“CB2” or the “Company”), a leading data-driven company focused on bringing Real-World Evidence driven from the point-of-care to the medical cannabis community, announced today that it has been selected as exclusive research technology platform for the leading, and only, independent scientific body on drugs in the UK, working to provide evidence-based information on safety and efficacy within medical cannabis.  A Letter of Intent has been signed between CB2 and Drug Science. “It is not often that a drug enters the market ahead of well established, widely held consensus on the health impact related to that drug,” said David Badcock, CEO, Drug Science.  “Project TWENTY21 has been designed to remove the barriers that come with a lack of evidence-based data so that physicians can become more confident, the industry can become more informed and patients can have access where and when cannabinoid treatment is appropriate.

  • GlobeNewswire

    CB2 Insights and Premier Health Group Move to Second Phase of Primary Care Physician Tools for Medical Cannabis Evaluations

    TORONTO, July 09, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIT) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the.

  • GlobeNewswire

    Premier Health and CB2 Insights Move to Second Phase of Primary Care Physician Tools for Medical Cannabis Evaluation

    Premier Health Group (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) (the “Company” or “Premier Health”), a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, has successfully completed Phase One of CB2 Insights’ (CSE:CBII) Clinical Decision Support (CDS) tool integration including targeted user testing.

  • GlobeNewswire

    CB2 Insights Expands Clinical Division into New Jersey with the Asset Acquisition of New Jersey Alternative Medicine Clinics

    OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced it will take over patient care for one of New Jersey’s largest medical cannabis evaluation and education clinic groups on July 1, 2019.  New Jersey Alternative Medicine (“NJAM”) will transfer all patient care to CB2 Insights under a performance-based agreement.  CB2 will operate within the State of New Jersey under the Company’s Canna Care Docs brand, the largest multi-state medical cannabis clinic operator in the US. The acquisition of assets of NJAM will require no cash or stock payments upon closing.

  • GlobeNewswire

    CB2 Insights Announces Annual General & Special Meeting of Shareholders and Corporate Update

    OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has announced the date of its first Annual General Meeting (AGM) and Special Meeting of Shareholders on June 27, 2019 at 10am EST at its head office at 5045 Orbitor Drive, Mississauga, ON. The AGM will provide an opportunity for CB2 Insights to present its shareholders, in-person, the latest updates and future growth opportunities aligned with its mission to be the largest aggregator and provider of Real World Data and Evidence (“RWD” and “RWE”) related to the safety, efficacy and effectiveness of medical cannabis and cannabis derived medications. Following a transformative year in 2018 and year-over-year and sequential growth in the first quarter of 2019, both organically and through M&A activity, the Company continues its effort to drive towards profitability.

  • GlobeNewswire

    CB2 Insights Posts Strong Growth in Clinical Revenue and Drives Operating Efficiencies in Q1 2019

    OTCQB:CBIIF) (“CB2” or the “Company”), a leading technology company focused on mainstreaming medical cannabis to the healthcare industry through Real World Evidence (“RWE”), today reported its results for the first quarter of 2019. Additional information concerning the Company, including its unaudited financial statements and related management’s discussion and analysis (“MD&A”) for the quarter ended March 31, 2019, can be found at www.sedar.com and on the Company’s website.

  • ACCESSWIRE

    CB2 Insights to Present at the 9th Annual LD Micro Invitational in Bel-Air

    OTCQB: CBIIF) ("CB2" or the "Company"), a leading data-analytics company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced that CEO Prad Sekar will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4 at 2:20PM PST / 5:20PM EST. Mr. Sekar is also scheduled to meet with investors throughout the day on June 4. "CB2 Insights has had several transformational catalysts since attending our first LD Micro event in December 2018," said Mr. Sekar.